Compare FND & FOLD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | FND | FOLD |
|---|---|---|
| Founded | 2000 | 2002 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | RETAIL: Building Materials | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.3B | 4.5B |
| IPO Year | 2014 | 2006 |
| Metric | FND | FOLD |
|---|---|---|
| Price | $53.22 | $14.46 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 16 | 9 |
| Target Price | ★ $77.25 | $27.25 |
| AVG Volume (30 Days) | ★ 2.9M | 2.6M |
| Earning Date | 04-30-2026 | 04-30-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 1.05 | ★ 50.00 |
| EPS | ★ 1.92 | N/A |
| Revenue | ★ $4,684,088,000.00 | N/A |
| Revenue This Year | $7.56 | $20.50 |
| Revenue Next Year | $7.78 | $18.59 |
| P/E Ratio | $26.09 | ★ N/A |
| Revenue Growth | ★ 5.12 | N/A |
| 52 Week Low | $46.47 | $5.66 |
| 52 Week High | $92.41 | $14.48 |
| Indicator | FND | FOLD |
|---|---|---|
| Relative Strength Index (RSI) | 48.33 | 66.60 |
| Support Level | $46.47 | $14.21 |
| Resistance Level | $64.23 | N/A |
| Average True Range (ATR) | 2.57 | 0.02 |
| MACD | 0.81 | -0.01 |
| Stochastic Oscillator | 87.19 | 75.00 |
Floor & Decor Holdings Inc operates as a specialty retailer in the hard surface flooring market. Its stores offer a range of tile, wood, laminate, and natural stone flooring products, as well as decorative and installation accessories at everyday low prices. It appeals to a variety of customers including professional installers, commercial businesses, Do It Yourself (DIY) customers, and customers who buy the products for professional installation. Geographically, the group has a presence in the United States region and also offers its product through an e-commerce site. The company segments include retail segment and others.
Amicus Therapeutics Inc is a biotechnology company focused to develop and deliver transformative medicines for people living with rare diseases. It has a portfolio of product opportunities, including oral precision medicine for people living with Fabry disease who have amenable genetic variants; a clinical-stage, treatment paradigm for Pompe disease, and a rare disease gene therapy portfolio. The company has one segment focused on the discovery, development, and commercialization of therapies to treat a range of devastating rare and orphan diseases.